In recent years emerging markets are gaining precedence in the pharmaceutical industry. Large populations and growing prosperity have made them attractive to investors, resulting in surging drug sales and booming markets.
The emerging markets Brazil, Russia, India, China and South Africa (BRICS) collectively have 2,800 pipeline products and 36,580 marketed products to date. Figure 1 shows that companies within these BRICS countries are actively developing products across cardiovascular, central nervous system (CNS), immunology, infectious disease, metabolic disorders, and oncology.
Go deeper with GlobalData
Oncology is shown to be the most predominant therapy area for companies developing pipeline drugs, with 226 companies. This is unsurprising considering oncology is the top research area in pharma; although, South Africa does not have any pipeline products in this area. There is also significant drug development in Infectious Disease, with more than three times as many companies choosing research in this therapy area than cardiovascular, CNS, immunology, and metabolic disorders: 118 companies compared with 28, 39, 33, and 39.
China has the highest number of companies in each of the six therapy areas in comparison to the other BRIC countries. India and Russia have the next highest number of companies and are involved in all six therapy areas, whereas South Africa and Brazil only have companies with pipeline products in CNS, Infectious Disease, and Oncology respectively.
See Also:
China’s expanding market in Infectious Disease is exemplified by the recent partnership with Johnson & Johnson and Phagelux, an anti-infectives biotech company based in China. The deal made in April 2017 takes advantage of Phagelux’s novel skin care technologies and Johnson & Johnson’s financial security with the promise of developing antibacterial solutions. Phagelux’s pipeline products included in the deal are topical treatments for burns, ulcers, acne vulgaris, and eczema, and are polymers mixed with biological agents: NJ-01SS, NJ-03BM, NJ-06FC, WH-01SZ. This deal highlights the rising potential of drug development and collaboration with China’s pharmaceutical companies within Infectious Diseases.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
